Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza nabs U.S. biologics site

by Rick Mullin
October 9, 2017 | A version of this story appeared in Volume 95, Issue 40

Lonza will acquire a clinical-stage mammalian biologics manufacturing site in Hayward, Calif., from the Irish drug company Shire. The 5,400-m2 facility, which has 1,000- and 2,000-L single-use bioreactors, will supplement the Swiss contract manufacturer’s clinical-stage capabilities in Slough, England. Lonza says it is offering the current staff of about 100 an opportunity to continue working at the site.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.